Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

An experimental oral drug called muvalaplin shows promise in reducing the cholesterol linked to heart disease in a study.

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Management at Eli Lilly has expressed strong confidence in the growing demand for their obesity franchise and a robust pipeline of new products. The company is anticipating significant benefits from ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...

On Friday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $746.2 which represents a decrease of $-40.03 or -5.09% from the prior close of $786.23. The stock opened at $775.19 and ...

The new mens range debuted at a VIP fashion show in Palm Beach last week, and will arrive in stores in February for the ...

Johnson & Johnson and Eli Lilly both sued the federal government this month over the future of their respective 340B drug rebate plans.

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

Evercore ISI analyst Umer Raffat maintained a Hold rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last ...